MiniMed Group, Inc.
MiniMed Group, Inc. develops and commercializes diabetes management technologies, including automated insulin delivery systems, continuous glucose monitoring products, and related smart dosing tools. The company serves patients and healthcare providers primarily in the United States and international markets through a portfolio centered on insulin pumps, sensors, and connected diabetes care platforms.
Fiscal year 2026 · change from previous year
Development 2025–2026
Business
Share of revenueInsulin pump systems that automate or assist insulin dosing for diabetes management.
Sensors and related CGM products used to track glucose levels and support dosing decisions.
Connected multiple daily injection solutions and software-enabled diabetes management tools.
Pump and sensor consumables, replacement components, and support services tied to installed users.
Products
Reported · share of revenue- Continuous Glucose Monitoring Systems CGM50.1 %
- Consumables30.8 %
- Pumps17.6 %
- Other1.5 %
Source: 10-K FY2026, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
MiniMed sells to people living with diabetes who need ongoing insulin therapy and glucose monitoring, with products designed for both pump users and users of connected injection workflows. Its commercial model also depends on healthcare providers, payers, and reimbursement systems that influence adoption, access, and renewal of therapy devices and sensors.
Patients using insulin pumps and integrated CGM systems for continuous diabetes management.
Patients buying sensors and integrated monitoring tools to improve glucose visibility and dosing decisions.
Patients using connected multiple daily injection solutions rather than full pump therapy.
Endocrinology and diabetes-care providers that influence product selection and therapy adoption.
Insurers and reimbursement systems that determine coverage and patient access to devices and sensors.
Strategy
MiniMed’s strategy centers on expanding its diabetes technology platform by pairing insulin pumps with CGM and connected dosing tools. The company is also focused on regulatory approvals, new product launches, and broader adoption of integrated therapy ecosystems that can increase revenue per user and strengthen retention.
A next-generation pump can refresh the product cycle and broaden the installed base.
Higher sensor attachment can increase recurring revenue and improve therapy integration.
Broader approvals support geographic expansion and faster product rollout.
Geography
Q1/2026MiniMed operates across the United States and international markets, with management noting especially strong demand for automated insulin delivery and CGM-enabled solutions outside the U.S. Geography matters because reimbursement rules, pricing pressure, regulatory approvals, and foreign currency movements all affect adoption and reported results.
Share of the revenue the company reports by geography.
Risks
MiniMed faces regulatory, reimbursement, and competitive risks typical of diabetes-device companies, where product adoption depends on approvals, payer coverage, and physician acceptance. The business is also exposed to pricing pressure in CGMs, foreign exchange volatility, and goodwill impairment risk because valuation depends heavily on projected revenue and cash flows.
- Reimbursement and pricing pressureImpact: HighLikelihood: High
Coverage decisions and competitive dynamics can reduce realized pricing, especially in CGMs.
Exposure: CGM portfolio and international markets
- Regulatory approval and clearance riskImpact: HighLikelihood: Medium
Product launches depend on FDA and foreign regulatory decisions, which can delay commercialization.
Exposure: MiniMed Flex and future pipeline products
- Goodwill impairmentImpact: HighLikelihood: Low
Valuation depends on projected revenue, cash flows, and discount rates, which are sensitive to market conditions.
Exposure: Single goodwill reporting unit
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
International sales and costs create translation and transaction exposure.
Exposure: Non-U.S. revenue and operations
Accounting
Judgemental itemsThe company uses income and market approaches with significant estimates, making valuation sensitive to forecast changes.
Impact: Could create material non-cash charges if fair value falls below carrying value
Future minimum royalty obligations can trigger large charges when milestones or approvals occur.
Impact: Can cause one-time expense recognition
Management excludes foreign currency and certain Italian payback accrual effects to assess underlying performance.
Impact: Affects comparability of reported growth trends
Similar listed companies
Publicly listed companies with a comparable business focus.
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Modular Medical, Inc.
MODD · Surgical & Medical Instruments & Apparatus
Senseonics Holdings, Inc.
SENS · Industrial Instruments For Measurement, Display, and Control
Beta Bionics, Inc.
BBNX · Surgical & Medical Instruments & Apparatus
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026